Neurobiology of Suicide
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02543983 |
Recruitment Status :
Recruiting
First Posted : September 9, 2015
Last Update Posted : May 17, 2024
|
Tracking Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | September 5, 2015 | ||||||||||
First Posted Date ICMJE | September 9, 2015 | ||||||||||
Last Update Posted Date | May 17, 2024 | ||||||||||
Actual Study Start Date ICMJE | December 1, 2015 | ||||||||||
Estimated Primary Completion Date | July 21, 2025 (Final data collection date for primary outcome measure) | ||||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||||
Change History | |||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||
Descriptive Information | |||||||||||
Brief Title ICMJE | Neurobiology of Suicide | ||||||||||
Official Title ICMJE | The Neurobiology of Suicide | ||||||||||
Brief Summary | Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies. They hope to better understand suicide, so they can help suicidal people. Objective: To understand what happens in the brain when someone has thought about or attempted suicide. Eligibility: Group 1: Adults ages 18 70 who have thought about or attempted suicide recently Group 2: Adults ages 18 70 who have thought about or attempted suicide in the past Group 3: Adults ages 18 70 who have depression or anxiety, but have never thought about suicide Group 4: Healthy volunteers the same ages. Design: Participants will be screened in another protocol. Adults who have recently thought about or attempted suicide must be referred by a doctor. They may do up to 3 phases of this study. Groups 2, 3 and 4 will do only Phase 1 and will not get ketamine. Phase 1: 1 week in hospital. Participants will have: Physical exam. Questions about thoughts and feelings. Thinking and memory tests and simple tasks. Blood and urine tests. Two MRI scans. Participants will lie on a table that slides into a metal cylinder that takes pictures. They will have a coil over their head and earplugs and do a computer task. Sleep test. Disks and bands will be placed on the body to monitor it during sleep. Magnetic detectors on their head while they perform tasks. A wrist monitor for activity and sleep. Lumbar puncture (optional). A needle will collect fluid from the back. Shock experiments (optional). Participants will observe pictures and sounds and feel a small shock on the hand. Phase 2: 4 days in hospital. A thin plastic tube will be placed in each arm, one for blood draws, the other to get the drug ketamine once. Participants will repeat most of the Phase 1 tests. Phase 3: up to 4 more ketamine doses over 2 weeks. Participants will have follow-up calls or visits at 6 months and then maybe yearly for 5 years. ... |
||||||||||
Detailed Description | A. Objective Suicide occurs across demographics and psychiatric disorders, killing at least one million individuals worldwide each year. In contrast to other injury-related death such as homicide or motor vehicle accidents, suicide rates have increased, particularly among middle-aged adults. Clinicians have a limited ability to predict imminent suicidal behavior and few, if any, efficacious treatments are available to treat suicidal patients. Advances in the treatment of the suicidal patients have been hampered by an incomplete understanding of the neurobiological underpinnings of the suicidal crisis, as suicidal thoughts and behaviors have not been clearly linked with specific neural circuits. The aim of this study is to evaluate possible biomarkers of suicidal thoughts and behaviors in individuals currently experiencing a suicidal crisis. In taking a dimensional approach to suicide research, we will be able to study phenomenology across Research Domain Criteria (RDoC) units of analysis, from genes through circuits to self-report and experimental paradigms. Through this approach, we can identify potential neurobiological risk factors for both short and long-term suicide risk. As a secondary aim, we will use ketamine to identify biomarkers of ketamine response in a sample at acute risk for suicide. B. Study Population Five participant populations will be recruited into this protocol in order to encompass the continuum of suicide risk. A total of 325 individuals will be enrolled in the study. Participant populations are individuals with the following conditions: 1.) recent suicidal ideation with intent and/or suicide attempt (Group 1- active crisis , n= 65); 2) a past history of suicide attempt, but no suicidal behavior in the last year (Group 2, n= 65, attempters ); 3) anxiety or mood symptoms, but no recent or past suicidal thoughts or behavior (Group 3, n= 65); 4) healthy controls with no psychiatric or suicide history (Group 4, n= 65); and lifetime suicidal thoughts with intent (Group 5, n=65, ideators ). C. Design The research protocol will occur across three phases: baseline, ketamine response and optional repeated infusions. All participants will first be consented into Phase I, which may last up to seven days. This baseline phase will entail multimodal assessment, using pathophysiological markers (blood draw, lumbar puncture), neuroimaging (fMRI, MEG), polysomnography, clinical ratings and experimental paradigms (shock experiments). Participants will receive their regularly scheduled daily medications, but will not receive additional treatment (including new prn medications, such as benzodiazepines for management of anxiety or agitation) during this brief baseline phase. After completion of Phase I, eligible participants from Group 1 or 5 only (active crisis or ideators) will be offered participation in Phase II, the ketamine response phase. This phase, which will last up to four days, consists of a single, open-label trial of ketamine (0.5 mg/kg). The focus of this phase will be identification of potential biomarkers of antisuicidal ketamine response. Participants who complete Phase II will be offered Phase III, which will involve repeated ketamine infusions over two weeks (2 times/ per week for 2 weeks). Psychiatric medication adjustment will be permitted during Phase III. After participation in Phases I-III, participants in Groups 1-3 and 5 will be offered standard clinical treatment (excluding healthy controls), or participation in another protocol. In standard clinical treatment, adjustment of psychiatric medications and commencement of psychotherapeutic interventions will be permitted. Finally, participants in Groups 1-3 and 5 will receive follow-up evaluations at six months after completion of Study Phase I. D. Outcome Measures In Phase I, the outcome measures will be underlying psychiatric, psychological, neuroimaging, sleep and biological differences between the participant groups. In Phase II, the outcome measures will be reductions in suicidal thoughts and depressive and anxiety symptoms at 24 hours post-ketamine infusion. |
||||||||||
Study Type ICMJE | Interventional | ||||||||||
Study Phase ICMJE | Phase 2 | ||||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science |
||||||||||
Condition ICMJE |
|
||||||||||
Intervention ICMJE |
|
||||||||||
Study Arms ICMJE | Experimental: 1
Ketamine Hydrochloride infusion
Interventions:
|
||||||||||
Publications * | Ballard ED, Park LT, Pao M, Zarate CA. Clinical Trials With Suicidal Individuals Can Be Conducted Safely. J Clin Psychiatry. 2020 Aug 4;81(5):20l13353. doi: 10.4088/JCP.20l13353. No abstract available. | ||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||
Recruitment Information | |||||||||||
Recruitment Status ICMJE | Recruiting | ||||||||||
Estimated Enrollment ICMJE |
325 | ||||||||||
Original Estimated Enrollment ICMJE |
170 | ||||||||||
Estimated Study Completion Date ICMJE | July 21, 2025 | ||||||||||
Estimated Primary Completion Date | July 21, 2025 (Final data collection date for primary outcome measure) | ||||||||||
Eligibility Criteria ICMJE |
Phase I: Groups 1-3 and 5 (Patients)
Phase I: Group 4 (Healthy Volunteers)
Phase II: Group 1 (Active Crisis) and Group 5 (Suicide Ideators)
Phase III: Group 1 (Active Crisis) and Group 5 (Suicide Ideators)
EXCLUSION CRITERIA: Phase I: Groups 1-3 and 5 (Patients)
monitoring the informed consent process will complete a capacity assessment. Participants who are determined not to have capacity to consent to research will not be included in the study. Phase I: Group 4 (Healthy Volunteers)
Exclusions for Imaging:
Phase II: Group 1 (Active Crisis) and Group 5 (Suicide Ideators)
Phase III: Repeated Administration (Group 1) and Group 5 (Suicide Ideators)
Exclusions for Imaging:
|
||||||||||
Sex/Gender ICMJE |
|
||||||||||
Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | ||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||
Contacts ICMJE |
|
||||||||||
Listed Location Countries ICMJE | United States | ||||||||||
Removed Location Countries | |||||||||||
Administrative Information | |||||||||||
NCT Number ICMJE | NCT02543983 | ||||||||||
Other Study ID Numbers ICMJE | 150188 15-M-0188 |
||||||||||
Has Data Monitoring Committee | Not Provided | ||||||||||
U.S. FDA-regulated Product |
|
||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||
Current Responsible Party | National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ) | ||||||||||
Original Responsible Party | Same as current | ||||||||||
Current Study Sponsor ICMJE | National Institute of Mental Health (NIMH) | ||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||
Collaborators ICMJE | Not Provided | ||||||||||
Investigators ICMJE |
|
||||||||||
PRS Account | National Institutes of Health Clinical Center (CC) | ||||||||||
Verification Date | March 4, 2024 | ||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |